IP Verse

Process For Manufacturing A Pharmaceutical Preparation Containing Glatiramer Acetate - EP3050556

The patent EP3050556 was granted to Teva Pharmaceuticals on Mar 22, 2017. The application was originally filed on Sep 24, 2015 under application number EP15186721A. The patent is currently recorded with a legal status of "Revoked".

EP3050556

TEVA PHARMACEUTICALS
Application Number
EP15186721A
Filing Date
Sep 24, 2015
Status
Revoked
Dec 18, 2020
Grant Date
Mar 22, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UK TRADING MYLANDec 22, 2017GILL JENNINGS & EVERYWITHDRAWN
WITTKOPPDec 21, 2017HAMM & WITTKOPPWITHDRAWN

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0693946
DESCRIPTIONUS7855176
OPPOSITIONUS2007054857
OPPOSITIONUS2013323771
OPPOSITIONWO2014128079
SEARCHUS2013323771

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MELTZER; JORNITZ, Filtration and Purification in the Biopharmaceutical Industry, CRC PRESS, (2007), page 166-
OPPOSITION- C. HERRERO et al., "Flux Decline in Protein Microfiltration: Influence of Operative Parameters", JOURNAL OF COLLOID AND INTERFACE SCIENCE, (19970000), vol. 187, pages 344 - 351, XP055449303-
OPPOSITION- Corning, "Innovative Products for Filtration and Ultrafiltration", Corning Filtration Guide, (20110000), XP055446776-
OPPOSITION- Development and Manufacture of Protein Pharmaceuticals, New York, (20020000), vol. 114, XP055449337-
OPPOSITION- FDA, "Copaxone (co-PAX-own) (fglatimer acetate injection) for subcutaneous use", Highlights of prescribing information, (20140128), XP055446759-
OPPOSITION- FDA, "Copaxone (co-PAX-own) (fglatimer acetate injection) for subcutaneous use", Patient information, (20140128), XP055446753-
OPPOSITION- "Filtration and Purification in the Biopharmaceutical Industry", DRUGS AND THE PHARMACEUTICAL SCIENCES, New York, (20080000), pages 521 - 522, XP055449330-
OPPOSITION- "Filtration Guide - Innovative products for filtration and ultrafiltration", CORNING, (20130000), pages 1 - 20, XP055446776-
OPPOSITION- "Media and Buffer Filtration Implications", M. W. JORNITZ et al., Drugs and the Pharmaceutical Sciences, Filtration and Purification in the Biopharmaceutical Industry, 2nd ed., CRC Press, (20080000), vol. 174, pages 439 - 457, XP055446769-
OPPOSITION- "Membrane Filtration", D. J. BROSE et al., Pharmaceutical Biotechnology, Development and manufacture of protein pharmaceuticals, New York, Kluwer Academic/Plenum Publishers, (20020000), vol. 14, pages 213 - 279, XP055446764-
OPPOSITION- RIPPERGER, S. et al., "Filtration, 1. Fundamentals", Ullmann's Encyclopedia of Industrial Chemistry, Weinheim, (20120000), XP055449267
OPPOSITION- C. HERRERO et al., "The effect of protein fouling in microfiltration and ultrafiltration on permeate flux, protein retention and selectivity: a literature review", Desalination, (19930000), vol. 91, no. 1, pages 65 - 108, XP055449320
SEARCH- Anonymous, "Copaxone, FDA Approved Labeling Text NDA 020622/S-089", (20140128), TEVA Pharmaceutical Industries Ltd., URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020622s089lbl.pdf, (20151102), XP002749999 [XD] 14,15 * points 2.1 and 11 *-
SEARCH- Anonymous, "Corning Filtration Guide", (2013), page 20PP, Corning Inc., URL: http://csmedia2.corning.com/lifesciences/media/pdf/t_filterselectionguide.pdf, (20151102), XP002750000 [A] 1-13 * page 6 *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents